dc.contributor | Departament de Salut |
dc.date.accessioned | 2018-06-18T12:35:40Z |
dc.date.available | 2018-06-18T12:35:40Z |
dc.date.issued | 2017-06-29 |
dc.identifier.citation | Selexipag per al tractament de la hipertensió arterial pulmonar. Barcelona: Servei Català de la Salut; 2017. |
dc.identifier.uri | https://hdl.handle.net/11351/3530 |
dc.description | Pulmonary arterial hypertension; Lung diseases; Selexipag |
dc.description.abstract | Pulmonary arterial hypertension (HAP) is a clinical, chronic and progressive condition that affects the pulmonary vasculature. It is characterized by the presence of pre-implanted pulmonary hypertension (HP), in the absence of other causes such as HP secondary to pulmonary disease or HP chronic thromboembolic disease, and by vascular resistance. The progressive increase in pressure And of the resistance can lead to right heart failure and, finally, to the premature death of the patient. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.relation.ispartof | Programa d'harmonització farmacoteràpeutica, Servei Català de la Salut |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ |
dc.source | Scientia |
dc.subject | Hipertensió pulmonar - Tractament |
dc.subject | Prostaciclina - Ús terapèutic |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Receptors, Epoprostenol |
dc.subject.mesh | Hypertension, Pulmonary |
dc.title | Selexipag per al tractament de la hipertensió arterial pulmonar |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | receptores de epoprostenol |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | hipertensión pulmonar |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |